Your session is about to expire
← Back to Search
Retinoid
Trifarotene 0.005 % Topical Cream for Acne
Phase 3
Waitlist Available
Research Sponsored by Teva Pharmaceuticals USA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 12 weeks
Awards & highlights
Pivotal Trial
Summary
This trial is testing a cream called Trifarotene to see if it is safe and effective for treating acne. Trifarotene is a newly FDA-labeled fourth-generation topical retinoid that shows promise in treating facial and truncal acne vulgaris. The study involves patients with acne who will use either the Trifarotene cream or another cream. The goal is to see if Trifarotene can help clear up acne by normalizing skin cell growth and reducing inflammation.
Eligible Conditions
- Acne
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Primary Change in Inflammatory Lesion Counts
Primary Change in Non-Inflammatory Lesion Count
Side effects data
From 2023 Phase 3 trial • 807 Patients • NCT055503372%
Application site dryness
2%
Nasopharyngitis
1%
Application site pain
1%
Headache
1%
Hypersensitivity
1%
Erythema
1%
Influenza
1%
Application site erythema
1%
Dysmenorrhoea
1%
Skin burning sensation
1%
Rhinitis
1%
Upper respiratory tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
AKLIEF®
Test: Trifarotene Cream, 0.005%
Vehicle Product
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Test: Trifarotene Cream, 0.005%Experimental Treatment1 Intervention
Trifarotene Cream, 0.005%, Apply to the affected areas of the face once daily for 84 days.
Group II: AKLIEF®Active Control1 Intervention
AKLIEF® (Trifarotene Cream, 0.005%), Apply to the affected areas of the face once daily for 84 days.
Group III: Vehicle ProductPlacebo Group1 Intervention
Vehicle of the Test Product, Cream, Apply to the affected areas of the face once daily for 84 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trifarotene 0.005 % Topical Cream
2022
Completed Phase 3
~810
Find a Location
Who is running the clinical trial?
Teva Pharmaceuticals, Inc.Industry Sponsor
Teva Pharmaceuticals USALead Sponsor
230 Previous Clinical Trials
187,401 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger